The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies
Open accessAbstract
OBJECTIVE: Anti-Hu antibodies (Hu-Ab) and anti-CV2/CRMP5 antibodies (CV2/CRMP5-Ab) have been identified in association with paraneoplastic neurological disorders. However, it is not clear whether these antibodies are associated with specific neurological symptoms or are only markers of anti-cancer immune reaction. METHODS: To address this question, 37 patients with CV2/CRMP5-Ab and 324 patients with Hu-Ab were compared. RESULTS: Whereas the age and sex ratio were the same between the two groups, the distribution of neurological symptoms was not. Patients with CV2/CRMP5-Ab presented more frequently cerebellar ataxia, chorea, uveo/retinal symptoms and myasthenic syndrome (Lambert-Eaton myasthenic syndrome LEMS or myasthenia gravis). They also had a better Rankin score. In contrast, dysautonomia, brainstem encephalitis and peripheral neuropathy were more frequent in patients with Hu-Ab. Limbic encephalitis occurred similarly in both groups. Small-cell lung cancer was the most frequently associated tumour in both groups of patients, while malignant thymoma was observed only in patients with CV2/CRMP5-Ab. In particular, patients with CV2/CRMP5-Ab and thymoma developed myasthenic syndrome more frequently, while patients with SCLC developed neuropathies more frequently. Chorea and myasthenic syndrome were only seen in patients with CV2/CRMP5-Ab. The median survival time was significantly longer in patients with CV2/CRMP5-Ab, and this effect was not dependent on the type of tumour. INTERPRETATION: The data demonstrate that in patients with paraneoplastic neurological syndromes, the neurological symptoms and survival vary with both the type of associated onco-neural antibody and the type of tumour.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recommended diagnostic criteria for paraneoplastic neurological syndromes
Graus, F. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.034447 · Cited by 1,610
Self-citationAnti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients
Graus, F. (2001) · Brain · doi:10.1093/brain/124.6.1138 · Cited by 897
Self-citationLucchinetti, C. F., Kimmel, D. W., & Lennon, V. A. (1998) · Neurology · doi:10.1212/wnl.50.3.652 · Cited by 499
PRIMARY SENSORY NEUROPATHY WITH MUSCULAR CHANGES ASSOCIATED WITH CARCINOMA
Denny-Brown, D. (1948) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.11.2.73 · Cited by 380
Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome
Pittock, S. J., Kryzer, T. J., & Lennon, V. A. (2004) · Annals of Neurology · doi:10.1002/ana.20269 · Cited by 319
Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP‐5‐IgG
Cross, S. A., Salomao, D. R., Parisi, J. E., Kryzer, T. J., Bradley, E. A., Mines, J. A., Lam, B. L., & Lennon, V. A. (2003) · Annals of Neurology · doi:10.1002/ana.10587 · Cited by 290
Paraneoplastic peripheral neuropathy associated with anti‐Hu antibodies
Camdessanché, J., Antoine, J., Honnorat, J., Vial, C., Petiot, P., Convers, P., & Michel, D. (2002) · Brain · doi:10.1093/brain/awf006 · Cited by 254
Self-citationParaneoplastic chorea associated with CRMP‐5 neuronal antibody and lung carcinoma
Vernino, S., Tuite, P., Adler, C. H., Meschia, J. F., Boeve, B. F., Boasberg, P., Parisi, J. E., & Lennon, V. A. (2002) · Annals of Neurology · doi:10.1002/ana.10178 · Cited by 228
Dalmau, J., Furneaux, H. M., Rosenblum, M. K., Graus, F., & Posner, J. B. (1991) · Neurology · doi:10.1212/wnl.41.11.1757 · Cited by 219
Self-citationGraus, F., Vega, F., Delattre, J. Y., Bonaventura, I., Reñé, R., Arbaiza, D., & Tolosa, E. (1992) · Neurology · doi:10.1212/wnl.42.3.536 · Cited by 186
Self-citation
Cited by
Chemotherapy‐induced peripheral neurotoxicity: A critical analysis
Park, S. B., Goldstein, D., Krishnan, A. V., Lin, C. S., Friedlander, M. L., Cassidy, J., Koltzenburg, M., & Kiernan, M. C. (2013) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21204 · Cited by 741
Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force
Titulaer, M. J., Soffietti, R., Dalmau, J., Gilhus, N. E., Giometto, B., Graus, F., Grisold, W., Honnorat, J., Sillevis Smitt, P. A. E., Tanasescu, R., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03220.x · Cited by 526
Self-citationNeuronal autoantigens—pathogenesis, associated disorders and antibody testing
Lancaster, E., & Dalmau, J. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.99 · Cited by 512
Metadata
- Authors
- Honnorat, J., Cartalat-Carel, S., Ricard, D., Camdessanche, J. P., Carpentier, A. F., Rogemond, V, Chapuis, F., Aguera, M., Decullier, E., Duchemin, A. M., Graus, F., & Antoine, J. C.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2008-12-09
- Volume
- 80
- Issue
- 4
- Pages
- 412-416
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W2134611639
- Cited by
- 272
- References
- 14
- FWCI
- 10.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. https://app.cochat.ai/papers/10.1136/jnnp.2007.138016
- The paper
- Honnorat, J., Cartalat-Carel, S., Ricard, D., Camdessanche, J. P., Carpentier, A. F., Rogemond, V, Chapuis, F., Aguera, M., Decullier, E., Duchemin, A. M., Graus, F., & Antoine, J. C. (2008). Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2007.138016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.